Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY J KUTTNER

Allopathic & Osteopathic Physicians Dermatology

NPI
1487614293
CMS profile
111852
Location
DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$47.55

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $47.55 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $19.66 1
Novartis Pharmaceuticals Corporation $14.34 1
Lilly USA, LLC $13.55 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY J KUTTNER

NPI 1487614293 · CMS profile ID 111852

Allopathic & Osteopathic Physicians / Dermatology

DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487614293?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487614293?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487614293?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1487614293?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $47.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $13.5508/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657690263 CMS
Celgene Corporation $19.6607/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672815901 CMS
Novartis Pharmaceuticals Corporation $14.3402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659563315 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47.55 3
PY2020 $77.30 5
PY2021 $264.26 16
PY2022 $165.30 8
PY2023 $138.69 6
PY2024 $4.04 1
PY2025 $51.95 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $700.00 1
PY2023 Principal investigator $16,868.27 29
PY2022 Principal investigator $44,738.46 42
PY2021 Recipient $11,453.00 4
PY2021 Principal investigator $67,841.53 50
PY2020 Principal investigator $261,290.81 68
PY2019 Recipient $27,860.00 6
PY2019 Principal investigator $204,941.02 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $80.00 12/30/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792488723
Principal investigator 1 Bausch Health US, LLC $4,222.35 12/22/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490821
Principal investigator 1 Bausch Health US, LLC $500.00 12/10/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490875
Principal investigator 1 ABBVIE INC. $1,251.25 12/02/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484943
Principal investigator 1 Bausch Health US, LLC $1,544.36 11/05/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490853
Principal investigator 1 PFIZER INC. $2,500.00 11/05/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832722763
Principal investigator 1 Bausch Health US, LLC $5,000.00 10/29/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490773
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $319.00 10/26/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901673
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $224.30 10/26/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901675
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $49.38 10/26/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901677
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $224.30 10/26/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901727
Principal investigator 1 ABBVIE INC. $42.50 10/07/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792478421
Principal investigator 1 Bausch Health US, LLC $250.00 10/01/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490797
Principal investigator 1 Bausch Health US, LLC $4,122.72 09/17/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490743
Principal investigator 1 ABBVIE INC. $3,635.00 09/07/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792474039
Principal investigator 1 Bausch Health US, LLC $1,961.10 08/20/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490719
Principal investigator 1 PFIZER INC. $2,500.00 08/14/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832818103
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $250.88 08/04/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901659
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $179.44 08/04/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901661
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $263.20 08/04/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901663
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $191.40 08/04/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901665
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $24.69 08/04/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901667
Principal investigator 1 Bausch Health US, LLC $5,450.00 07/30/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490664
Principal investigator 1 Bausch Health US, LLC $250.00 07/30/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490691
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $3,500.00 07/13/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 07/12/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 793105759
Principal investigator 1 ABBVIE INC. $160.00 07/07/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792466719
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 07/01/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901669
Principal investigator 1 ABBVIE INC. $2,502.50 06/30/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792464835
Principal investigator 1 ABBVIE INC. $2,475.00 06/29/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792464377
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.00 06/28/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901651
Recipient Bausch Health US, LLC $5,643.00 06/07/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850473999
Recipient Bausch Health US, LLC $2,500.00 06/07/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850474119
Principal investigator 1 ABBVIE INC. $500.00 06/01/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792461395
Principal investigator 1 PFIZER INC. $100.00 05/08/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832887013
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 05/06/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901657
Principal investigator 1 PFIZER INC. $90.50 04/22/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832792571
Principal investigator 1 PFIZER INC. $1,876.50 04/22/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832800775
Recipient Bausch Health US, LLC $3,060.00 04/19/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850474082
Recipient Bausch Health US, LLC $250.00 04/12/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850474043
Principal investigator 1 PFIZER INC. $1,701.00 04/09/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832769941
Principal investigator 1 ABBVIE INC. $3,677.50 03/30/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792437411
Principal investigator 1 PFIZER INC. $2,314.63 03/24/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832702565
Principal investigator 1 PFIZER INC. $1,181.25 03/24/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832861345
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.08 03/18/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901653
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $255.20 03/18/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852901655
Principal investigator 1 Bausch Health US, LLC $652.50 03/01/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490641
Principal investigator 1 PFIZER INC. $140.50 02/24/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832717669
Principal investigator 1 Bausch Health US, LLC $250.00 02/22/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490582
Principal investigator 1 PFIZER INC. $1,755.00 02/05/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832856523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 01/26/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 793092909
Principal investigator 1 Bausch Health US, LLC $4,401.00 01/25/2021 Non-covered Recipient Entity
Integrated Clinical Research
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850490611
Principal investigator 1 ABBVIE INC. $2,707.50 01/21/2021 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy No dispute reported 06/30/2026 792411137
Principal investigator 1 PFIZER INC. $1,830.00 01/09/2021 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832722643